Strongbridge Biopharma plc to Participate in the JMP Securities Life Science Conference
June 13 2017 - 7:30AM
Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs, today announced that management will participate
in the JMP Securities Life Science Conference. Matthew Pauls,
president and chief executive officer of Strongbridge Biopharma,
will take part in a panel discussion titled, “Developing and
Commercializing Drugs for Rare Diseases,” on Tuesday, June 20 at
10:30 a.m. ET. The conference will take place at the St.
Regis in New York, NY.
About Strongbridge
Biopharma Strongbridge
Biopharma is a global commercial-stage biopharmaceutical
company focused on the development and commercialization of
therapies for rare diseases with significant unmet needs.
Strongbridge's first commercial product is KEVEYIS®
(dichlorphenamide), the first and only FDA-approved treatment
for hyperkalemic, hypokalemic, and related variants of Primary
Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in
the U.S. through August 7, 2022. In addition to establishing
this neuromuscular disease franchise, the Company has a
clinical-stage pipeline of therapies for rare endocrine diseases.
Strongbridge's lead compounds include
RECORLEV™ (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and veldoreotide, a next-generation
somatostatin analog being investigated for the treatment of
acromegaly, with potential additional applications in Cushing's
syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide
have received orphan designation from the U.S. Food and Drug
Administration and the European Medicines Agency. For
more information, visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2023 to Apr 2024